{"organizations": [], "uuid": "0b02ced9c9ce4a9f4f5284c0c715514632505746", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-grifols-receives-fda-approval-for/brief-grifols-receives-fda-approval-for-new-formulation-of-its-rabies-virus-treatment-idUSASB0C493", "country": "US", "domain_rank": 408, "title": "BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T16:57:00.000+02:00", "replies_count": 0, "uuid": "0b02ced9c9ce4a9f4f5284c0c715514632505746"}, "author": "", "url": "https://www.reuters.com/article/brief-grifols-receives-fda-approval-for/brief-grifols-receives-fda-approval-for-new-formulation-of-its-rabies-virus-treatment-idUSASB0C493", "ord_in_thread": 0, "title": "BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment", "locations": [], "entities": {"persons": [], "locations": [{"name": "new formu", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "rabies virus treatment reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 6, 2018 / 2:58 PM / Updated 4 minutes ago BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment Reuters Staff 1 Min Read \nFeb 6 (Reuters) - Grifols SA: \n* GRIFOLS HYPERRABÂ® (RABIES IMMUNE GLOBULIN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-02-06T16:57:00.000+02:00", "crawled": "2018-02-06T17:04:17.014+02:00", "highlightTitle": ""}